TRULIEVE CANNABIS CORP

Trulieve Cannabis Corp. is a leading medical‑cannabis company, delivering high‑quality products for serious conditions like cancer, with a $1.99 B market cap and strong growth potential.

Trulieve Cannabis Corp. trades OTC with a $1.78 bn market cap, focusing on medical‑cannabis products for serious illnesses, yet remains unprofitable.

Trulieve Cannabis Corp expands in Florida, posts Q1 2026 profits and strong cash flow, boosting market share and investor confidence.

Trulieve Cannabis Corp prepares Q1 2026 results amid Florida expansion, regulatory shifts and volatile stock performance—discover key insights for investors.

Trulieve Cannabis faces a potential federal reclassification that could lower taxes and boost capital access, while new Florida stores and sustainability initiatives signal growth and stronger investor confidence.

Trulieve Cannabis Corp capitalizes on Colorado’s new hospital‑access law for terminal patients, expanding market reach and boosting investor confidence in medical cannabis.

Trulieve cuts 58 call‑center jobs to boost tech‑driven support, freeing capital for growth in newly legal U.S. states and a rapidly expanding global cannabis market.

Trulieve Cannabis Corp’s 2026 stock review: market cap, price swings, regulatory strategy, and future growth outlook for the U.S. medical cannabis industry.

Trulieve Cannabis Corp: stock dips amid regulatory uncertainty, but medical‑cannabis focus keeps investors hopeful for future growth.

Trulieve Cannabis Corp raises $100 M in senior notes, boosting liquidity and fueling growth while navigating market volatility in the medical cannabis sector.